The DETECT study: Personalised treatment in advanced breast cancer based on circulating tumour cells

11th December 2015

At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of the DETECT study, which was designed to evaluate the prognostic and predictive value of HER2-status of circulating tumour cells in patients with metastatic breast cancer.

The DETECT study: Personalised treatment in advanced breast cancer based on circulating tumour cells

Navigating the Integration of Immuno-Oncology Into the Perioperative Muscle-Invasive Urothelial Carcinoma Treatment Landscape

Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine

More articles

EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives

Infographic: ESMO Recommendations for Diagnosis and Staging of Metastatic Non-Small-Cell Lung Cancer

Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer

Featured journals

EMJ Oncology 10 [Supplement 12] 2022

EMJ Oncology 10 [Supplement 11] 2022

Therapeutic Area

About Us

The DETECT study: Personalised treatment in advanced breast cancer based on circulating tumour cells

Related To This Subject

Navigating the Integration of Immuno-Oncology Into the Perioperative Muscle-Invasive Urothelial Carcinoma Treatment Landscape

Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine

More articles

EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives

Infographic: ESMO Recommendations for Diagnosis and Staging of Metastatic Non-Small-Cell Lung Cancer

Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer

Featured journals

EMJ Oncology 10 [Supplement 12] 2022

EMJ Oncology 10 [Supplement 11] 2022

Join our mailing list